![Karim Dabbagh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karim Dabbagh
Chairman at
MAAT PHARMA
Net worth: 851 362 $ as of 2026-07-30
Profile
Karim Dabbagh was the founder of Modus Biomedicine, Inc., founded in 2009, and served as Chief Executive Officer from 2009 to 2010.
Current jobs include Chief Executive Officer at Dualitas Therapeutics, Inc. starting in 2026, and Independent Chairman at Maat Pharma SA starting in 2023.
Former job includes President, Chief Executive Officer & Director at Second Genome, Inc. from 2018 to 2023.
Education includes undergraduate studies at Imperial College London and a doctorate from University College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MAAT PHARMA 1.41% | 2025-03-30 | 266,173 ( 1.41% ) | 851 362 $ | 2026-07-30 |
Karim Dabbagh active positions
| Companies | Position | Start |
|---|---|---|
| MAAT PHARMA | Chairman | 2023-06-20 |
Former positions of Karim Dabbagh
| Companies | Position | End |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Chief Executive Officer | 2023-08-31 |
Modus Biomedicine, Inc. | Chief Executive Officer | 2010-11-30 |
Training of Karim Dabbagh
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
33
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Maat Pharma SA
 Maat Pharma SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | Health Technology |
Modus Biomedicine, Inc. |
- Stock Market
- Insiders
- Karim Dabbagh
